Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
33.61
+0.24 (0.72%)
May 29, 2026, 4:00 PM EDT - Market closed
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 796.33 | 780.57 | 631.45 | 566.77 | 463.93 | 276.87 | |
Revenue Growth (YoY) | 19.88% | 23.61% | 11.41% | 22.17% | 67.56% | -10.69% |
Cost of Revenue | 313.15 | 317.31 | 254.11 | 240.6 | 254.45 | 126.25 |
Gross Profit | 483.18 | 463.26 | 377.34 | 326.17 | 209.49 | 150.62 |
Selling, General & Admin | 294.73 | 284.8 | 210.36 | 159.21 | 172.19 | 118.96 |
Research & Development | - | - | - | - | 3.98 | 9.45 |
Other Operating Expenses | -0.4 | -1.18 | -2.91 | - | - | 4.58 |
Total Operating Expenses | 294.33 | 283.62 | 207.45 | 159.21 | 176.17 | 132.99 |
Operating Income | 188.85 | 179.64 | 169.9 | 166.96 | 33.32 | 17.63 |
Interest Income | 12.77 | 11.29 | 13.98 | 15.62 | 1.05 | 0.01 |
Interest Expense | -77.38 | -82.31 | -73.97 | -83.34 | -63.21 | -21.01 |
Other Non-Operating Income (Expense) | -15.99 | -15.99 | -11.33 | -23.5 | - | - |
Total Non-Operating Income (Expense) | -80.61 | -87.02 | -71.33 | -91.23 | -62.17 | -21 |
Pretax Income | 108.24 | 92.62 | 98.57 | 75.73 | -28.85 | -3.37 |
Provision for Income Taxes | 33.29 | 29.75 | 29.38 | 27.58 | -3.85 | -74.89 |
Net Income | 74.95 | 62.87 | 69.19 | 48.16 | -25 | 71.52 |
Net Income to Common | 74.95 | 62.87 | 69.19 | 48.16 | -25 | 71.52 |
Net Income Growth | 70.75% | -9.13% | 43.68% | - | - | 167.33% |
Shares Outstanding (Basic) | 32 | 32 | 32 | 34 | 34 | 35 |
Shares Outstanding (Diluted) | 40 | 40 | 40 | 42 | 34 | 41 |
Shares Change (YoY) | 3.36% | -1.79% | -3.26% | 23.53% | -17.58% | 16.77% |
EPS (Basic) | 2.37 | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 |
EPS (Diluted) | 2.04 | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 |
EPS Growth | 67.21% | -6.99% | 44.19% | - | - | 144.74% |
Shares Outstanding | 32.41 | 31.71 | 31.44 | 31.87 | 33.85 | 33.66 |
Free Cash Flow | 329.83 | 327.58 | 203.33 | 274.29 | 122.61 | 101.61 |
Free Cash Flow Growth | 0.69% | 61.11% | -25.87% | 123.71% | 20.66% | 14.95% |
Free Cash Flow Per Share | 8.32 | 8.25 | 5.03 | 6.56 | 3.62 | 2.48 |
Gross Margin | 60.68% | 59.35% | 59.76% | 57.55% | 45.15% | 54.40% |
Operating Margin | 23.71% | 23.01% | 26.91% | 29.46% | 7.18% | 6.37% |
Profit Margin | 9.41% | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% |
FCF Margin | 41.42% | 41.97% | 32.20% | 48.40% | 26.43% | 36.70% |
EBITDA | 358.82 | 405.71 | 339.06 | 316.22 | 172.26 | 86.55 |
EBITDA Margin | 45.06% | 51.98% | 53.69% | 55.79% | 37.13% | 31.26% |
EBIT | 188.85 | 179.64 | 169.9 | 166.96 | 33.32 | 17.63 |
EBIT Margin | 23.71% | 23.01% | 26.91% | 29.46% | 7.18% | 6.37% |
Effective Tax Rate | 30.75% | 32.12% | 29.80% | 36.41% | 13.33% | 2219.65% |